Anavex Lf SC (AVXL)

Jan 15, 2025, 7:30 AM EST - 2 days ago

Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III Data in The Journal of Prevention of Alzheimer's Disease

Jan 13, 2025, 7:30 AM EST - 4 days ago

New Phase IIb/III Clinical Data Demonstrates Over Three Years of Continuous Treatment with Oral Blarcamesine to Significantly Benefit Early Alzheimer's Disease Patients

Jan 12, 2025, 11:21 AM EST - 5 days ago

Playing The Odds Of Anavex Alzheimer's Drug Approval

Jan 6, 2025, 7:30 AM EST - 11 days ago

Anavex Life Sciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 27, 2024, 7:30 AM EST - 21 days ago

Anavex Life Sciences: Jumping In On-Time Ahead Early Alzheimer's Decision

Dec 26, 2024, 10:31 AM EST - 22 days ago

Kemper To Rally More Than 25%? Here Are 4 Top Analyst Forecasts For Thursday

KMPR ACVA PYPD

Dec 24, 2024, 8:50 AM EST - 24 days ago

Anavex Life Sciences: Why I Am Still Not Buying The Bull Thesis

Dec 23, 2024, 10:23 AM EST - 25 days ago

Anavex Life Sciences Corp. (AVXL) Q4 2024 Earnings Call Transcript

Dec 23, 2024, 7:30 AM EST - 25 days ago

Anavex Life Sciences Reports Fiscal 2024 Fourth Quarter Financial Results and Provides Business Update

Dec 23, 2024, 7:00 AM EST - 25 days ago

Blarcamesine Receives EMA Filing Acceptance for Treatment of Alzheimer's Disease

Dec 16, 2024, 7:30 AM EST - 4 weeks ago

Anavex Life Sciences to Announce Fiscal 2024 Fourth Quarter Financial Results on Monday, December 23, 2024

Dec 9, 2024, 7:30 AM EST - 5 weeks ago

Anavex Life Sciences to Report New Long-Term Oral Blarcamesine Phase IIb/III Alzheimer's Disease Data at J.P. Morgan 2025 Healthcare Conference

Dec 2, 2024, 7:30 AM EST - 6 weeks ago

Anavex Life Sciences to Present at the 7th Annual Evercore ISI HealthCONx Conference 2024

Nov 26, 2024, 7:30 AM EST - 7 weeks ago

Anavex Life Sciences Announces Submission of Blarcamesine MAA for Treatment of Alzheimer's Disease to EMA

Nov 25, 2024, 7:30 AM EST - 7 weeks ago

Anavex Life Sciences Announces Acceptance of Peer-Reviewed Manuscript of Oral Blarcamesine Phase IIb/III Data in a Reference Alzheimer's Disease Journal

Nov 6, 2024, 5:10 AM EST - 2 months ago

Anavex Life Sciences: Weighing The Pros And Cons Of A Possible EU Approval Scenario

Oct 31, 2024, 4:00 AM EDT - 2 months ago

Anavex's Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer's Trial: Data Presented at CTAD Conference 2024

Oct 17, 2024, 7:30 AM EDT - 3 months ago

Anavex Life Sciences Announces Encouraging Preliminary Biomarker Results from Ongoing Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia

Sep 3, 2024, 7:30 AM EDT - 4 months ago

Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024

Aug 6, 2024, 12:19 PM EDT - 5 months ago

Anavex Life Sciences Corp. (AVXL) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 7:30 AM EDT - 5 months ago

Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update

Aug 1, 2024, 7:30 AM EDT - 6 months ago

Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024

Jul 30, 2024, 7:30 AM EDT - 6 months ago

Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X Conference

Jul 28, 2024, 5:00 PM EDT - 6 months ago

Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association Conference

Jun 20, 2024, 7:30 AM EDT - 7 months ago

Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

May 22, 2024, 7:30 AM EDT - 8 months ago

Anavex Life Sciences Announces Expansion of Leadership Team

May 14, 2024, 7:30 AM EDT - 8 months ago

Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ

May 13, 2024, 1:45 PM EDT - 8 months ago

FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in Anavex Life Sciences Corp. with Losses of $500,000 to Contact the Firm

May 10, 2024, 1:15 PM EDT - 9 months ago

FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in Anavex Life Sciences Corp. with Losses of $500,000 to Contact the Firm

May 9, 2024, 8:43 PM EDT - 9 months ago

Annovis, Anavex, And Cassava Sciences: Trying To Box Oneself Out Of The Alzheimer's Box

SAVA ANVS

May 9, 2024, 7:30 AM EDT - 9 months ago

Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update

May 8, 2024, 11:15 PM EDT - 9 months ago

FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in Anavex Life Sciences Corp. with Losses of $100,000 to Contact the Firm

May 3, 2024, 5:45 AM EDT - 9 months ago

Anavex Life Sciences Corporation Sued for Securities Law Violations - Contact The Gross Law Firm Before May 13, 2024 to Discuss Your Rights - AVXL

May 2, 2024, 7:30 AM EDT - 9 months ago

Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024

Apr 25, 2024, 10:00 AM EDT - 9 months ago

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Anavex

Apr 16, 2024, 5:45 AM EDT - 9 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 13, 2024 in Anavex Life Sciences Lawsuit - AVXL